Hematologic Malignancy
Adult Acute Lymphoblastic Leukemia
CI-CAN-00001706Explore in graph →
Hematologic44 active trials2 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001706Explore in graph →
Clinical trials
249 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (37)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05487651 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies(ANCHOR2) | unknown | Phase 1 | 36 | Athenex, Inc.INDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT05679687 | ThisCART19A Bridging to alloHSCT for R/R B-ALL | unknown | Phase 1 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT04740203 | Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL | unknown | Phase 1 / Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT04516551 | Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT | unknown | Phase 1 | 18 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT03110640 | Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | unknown | Phase 1 | 20 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT03185494 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT01735604 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Sep 29, 2015 | clinicaltrials |
Data updated 22 days agoSource updated May 18, 2023source: clinicaltrials